Karo Pharma - Pfizer Collaboration reaches second milestone

Karo Pharma has received a milestone for the RORgamma project amounting to 2 million USD.

“This is the second milestone-payment for RORgamma. Very good news for the project” says Anders Lönner, Chairman of the Board.

For further information, please contact :
Henrik Palm, CFO,
Telephone +46 70 540 40 14 or
E-mail henrik.palm@karopharma.se

The information in this report is such that Karo Pharma is obliged to make public pursuant to the EU Market Abuse Regulation and the Securities Markets Act. The information was submitted for publication, through the agency of the contact person set out above, on May 4, 2016 at 3.00 p.m. CET.


About Us

The mission of Karo Bio is to develop novel pharmaceuticals for treatment of metabolic diseases. The company is in an exciting stage of its development and is transforming from a drug discovery company to a company with preclinical and clinical development capabilities. I welcome you to our website and encourage you to learn more about our clinical and preclinical programs and our partnerships


Documents & Links